Study on the Effect of PEG-IFNα-2b Assisted Entecavir in the Treatment of HBeAg-negative Chronic Hepatitis B
Objective:To explore the feasibility and effectiveness of entecavir combined with PEG-IFNα-2b in patients with HBeAg-negative chronic hepatitis B,so as to provide reference for clinical treatment.Methods:A total of 80 patients with HBeAg-negative chronic hepatitis B admitted to our hospital from April 2017 to April 2019 were selected and divided into control group(45 patients)and observation group(35 patients)according to different treatment methods.The control group was treated with entecavir,and the observation group was treated with PEG-IFNα-2 b on the basis of the control group.The liver function indexes,liver fibrosis level,quality of life and HBsAg clearance rate were compared between the two groups before and after treatment.Results:The levels of total bilirubin,indirect bilirubin,direct bilirubin,alanine aminotransferase,aspartate aminotransferase,alpha-fetoprotein,laminin,hyaluronic acid and typeⅢ procollagen in the observation group were lower than those in the control group(P<0.05).After treatment,the QLS-CHB scores of physiology,symptoms,psychology and society in the observation group were higher than those in the control group(P<0.05).After 12 months of follow-up,the HBsAg clearance rate in the observation group was 25.71%,which was higher than 2.22%in the control group(P<0.05).Conclusion:Entecavir combined with PEG-IFNα-2b has a good application effect in the treatment of HBeAg-negative chronic hepatitis B patients,and has a positive impact on improving the liver function index and HBsAg clearance rate of patients.
NETL
NSTL
万方数据
